Active Not Recruiting
PHASE1
INTERVENTIONAL
NCT06267092
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months. Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.
Interventions
Name:
No treatment given
Type:
OTHER
Description:
Participants will not get any medicine during this study.
Name:
Cagrilintide and Semaglutide
Type:
DRUG
Description:
Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
Name:
Placebo
Type:
DRUG
Description:
Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Primary Outcomes
Measure:
Change in mean postprandial appetite score based on visual analogue scale (VAS)
TimeFrame:
Baseline to week 24
Description:
Measured in millimeter. VAS appetite questions record the participants' sensations within Hunger, Satiety, Fullness and Prospective food consumption by the participants on a paper printed scale line from 0 to 100 mm. The appetite score will be calculated as \[hunger + (100 - satiety) + (100 - fullness) + prospective food consumption\]/4. Scores of 0 mm are worst and scores of 100 mm are best.
Trial Information
NCT ID
NCT06267092
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025